Reshma Kewalramani, Vertex CEO
July 11, 2022 10:55 AM EDTUpdated 11:16 AM
Deals
Cell/Gene Tx

Ver­tex nabs Vi­a­Cyte's ri­val di­a­betes stem cell treat­ment, ac­quir­ing the biotech for $320M in cash

Max Gelman

Senior Editor

Less than a week af­ter the FDA lift­ed a hold on Ver­tex’s stem cell ther­a­py for type 1 di­a­betes, the Boston com­pa­ny is buy­ing out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times